Cargando…

Local consolidative therapy for synchronous oligometastatic non‐small cell lung cancer treated with first‐line pembrolizumab: A retrospective observational study

BACKGROUND: Local consolidative therapy (LCT) has emerged as a treatment option in patients with oligometastatic non‐small cell lung cancer (NSCLC) undergoing chemotherapy or targeted therapy. However, the current literature lacks evidence as to whether LCT improves survival in NSCLC patients receiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ya, Wang, Yanan, Yang, Zhengyu, Hu, Minjuan, Lu, Jun, Zhang, Yanwei, Qian, Fangfei, Zhang, Bo, Wang, Shuyuan, Wang, Kai, Zhang, Wei, Han, Baohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888157/ https://www.ncbi.nlm.nih.gov/pubmed/35060346 http://dx.doi.org/10.1111/1759-7714.14312

Ejemplares similares

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer
por: Yang, Zhengyu, et al.
Publicado: (2022)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung
por: Wang, Yanan, et al.
Publicado: (2021)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer
por: Santos, Patricia Mae G., et al.
Publicado: (2022)

Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
por: Bai, Hao, et al.
Publicado: (2016)

ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients
por: Lu, Jun, et al.
Publicado: (2021)

PlGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/β-catenin pathway
por: Zhang, Wei, et al.
Publicado: (2021)

First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations
por: Hu, Xiaolong, et al.
Publicado: (2022)

Imaging modalities in synchronous oligometastatic prostate cancer
por: Futterer, Jurgen J., et al.
Publicado: (2018)

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2021)

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
por: Zhao, Yiming, et al.
Publicado: (2021)

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer
por: Wang, Xiao-Shan, et al.
Publicado: (2022)

Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor
por: Hu, Xiaolong, et al.
Publicado: (2021)

Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study
por: Gomez, Daniel R., et al.
Publicado: (2016)

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)
por: Miyawaki, Taichi, et al.
Publicado: (2021)

The metabolic repression effect of carbon-ion radiotherapy in synchronous hormone-sensitive oligometastatic prostate cancer
por: Zhang, Zhenshan, et al.
Publicado: (2023)

Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer
por: Jones, Gregory D., et al.
Publicado: (2021)

Survival Outcomes After Radiotherapy for the Treatment of Synchronous Oligometastatic Prostate Cancer
por: Huynh, Linda My, et al.
Publicado: (2022)

Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives
por: Almeldin, Doaa Said, et al.
Publicado: (2020)

Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
por: Li, Yujing, et al.
Publicado: (2022)

Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma - A case-control study
por: Shao, Yi, et al.
Publicado: (2020)

Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma
por: Shi, Zhenguo, et al.
Publicado: (2022)

Definitive Chemoradiation Associated with Improved Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Cancer
por: Matoska, Thomas, et al.
Publicado: (2023)

Metastasis-Directed Radiation Therapy with Consolidative Intent for Oligometastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Longo, Nicola, et al.
Publicado: (2022)

Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study
por: Chen, Ya, et al.
Publicado: (2023)

A Pilot Trial of Pembrolizumab plus Prostatic Cryotherapy for Men with Newly Diagnosed Oligometastatic Hormone-Sensitive Prostate Cancer
por: Ross, Ashley E., et al.
Publicado: (2019)

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol
por: Pryor, David, et al.
Publicado: (2021)

Risk Prediction Model for Synchronous Oligometastatic Non-Small Cell Lung Cancer: Thoracic Radiotherapy May Not Prolong Survival in High-Risk patients
por: Meng, Chunliu, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease
por: Mehrens, Dirk, et al.
Publicado: (2021)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Robotic treatment of oligometastatic kidney tumor with synchronous pancreatic metastasis: case report and review of the literature
por: Boni, Andrea, et al.
Publicado: (2018)

Local therapy treatment conditions for oligometastatic non-small cell lung cancer
por: Zhang, Suli, et al.
Publicado: (2022)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma
por: Hu, Minjuan, et al.
Publicado: (2020)

Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance
por: Li, Yujing, et al.
Publicado: (2023)

Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis
por: Song, Ying-Qiu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7qhtaqa4va4j58c3i59num16g5